Accepted for Publication: March 4, 2013.
Published Online: July 15, 2013. doi:10.1001/jamaneurol.2013.3124.
Acquisition of data: Matiello, Schaefer-Klein, Sun.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Weinshenker.
Critical revision of the manuscript for important intellectual content: Matiello, Schaefer-Klein, Sun.
Obtained funding: Weinshenker.
Administrative, technical, and material support: All authors.
Study supervision: Weinshenker.
Conflict of Interest Disclosures: Dr Weinshenker reports serving on data safety monitoring boards for Novartis, Biogen Idec, and Mitsubishi; receiving payment for consultation from Elan Pharmaceuticals, Asahi Kasei Kuraray Medical Co, Ltd, GlaxoSmithKline Pharmaceuticals, and Ono Pharmaceuticals; serving on the editorial boards of the Canadian Journal of Neurological Sciences, the Turkish Journal of Neurology, and the Multiple Sclerosis Journal; receiving research support from the Guthy-Jackson Charitable Foundation; and receiving license royalties from RSR Ltd for a patent regarding AQP4-associated antibodies for diagnosis of NMO.
Funding/Support: This work was supported by grants from the Guthy-Jackson Charitable Foundation (Dr Weinshenker) and by postdoctoral fellowship grants from the National Multiple Sclerosis Society (Dr Matiello).
Additional Contributions: Michael Fautsch, PhD (Department of Ophthalmology, Mayo Clinic, Rochester), provided archived human optic nerve samples. Vanda Lennon, MD, PhD, and James Fryer, MS, provided stable cell lines expressing M1 and M23 human isoforms for use as molecular weight markers.